EPRX
Eupraxia Pharmaceuticals Inc. Common Stock (EPRX)
Healthcare • NASDAQ • $7.45-0.27%
- Symbol
- EPRX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $7.45
- Daily Change
- -0.27%
- Market Cap
- $458.20M
- Trailing P/E
- N/A
- Forward P/E
- -11.46
- 52W High
- $9.32
- 52W Low
- $3.67
- Analyst Target
- $14.79
- Dividend Yield
- N/A
- Beta
- 1.42
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in …
Company websiteResearch EPRX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.